View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Dermapharm Holding SE: 1 director

A director at Dermapharm Holding SE bought 1,800,000 shares at 40.680EUR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

 PRESS RELEASE

EQS-News: Dermapharm Holding SE steigert den Umsatz planmäßig und über...

EQS-News: Dermapharm Holding SE / Schlagwort(e): Jahresergebnis/Vorläufiges Ergebnis Dermapharm Holding SE steigert den Umsatz planmäßig und übertrifft Prognose des bereinigten Konzern-EBITDAs 14.03.2025 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Dermapharm Holding SE steigert den Umsatz planmäßig und übertrifft Prognose des bereinigten Konzern-EBITDAs   Konzernumsatz erhöht sich um 4,0 % auf 1.180,8 Mio. € getrieben durch starkes organisches Wachstum im Segment „Markenarzneimittel“ Konzern-EBITDA (unbereinigt) steigt...

 PRESS RELEASE

EQS-News: Dermapharm Holding SE increases revenue as projected and exc...

EQS-News: Dermapharm Holding SE / Key word(s): Annual Results/Preliminary Results Dermapharm Holding SE increases revenue as projected and exceeds guidance for adjusted consolidated EBITDA 14.03.2025 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Dermapharm Holding SE increases revenue as projected and exceeds guidance for adjusted consolidated EBITDA   Consolidated revenue up 4.0% to EUR 1,180.8 million, driven by strong organic growth in the "Branded pharmaceuticals" segment Above-average increase in unadjusted consolidated E...

Oliver Metzger ... (+2)
  • Oliver Metzger
  • Stephan Wulf

Dermapharm Holding SE : Strong 9M results, increased earnings quality ...

>Strong 9M reflected first improvements of Other Healthcare Products… - Dermapharm released a set of strong 9M figures, which were basically supported by all divisions. 9M sales of € 890m (+3%) came in 1% above our (€ 886m) and 2% above the consensus compiled by the company of € 871m. Adjusted EBITDA of € 240m (-1%) was 5% above our estimates of € 229m and 8% above the consensus of € 223m. The slightly lower profitability vs 9M 2023 (adjusted EBITDA margin of 27% vs 2...

Oliver Metzger ... (+2)
  • Oliver Metzger
  • Stephan Wulf

Dermapharm Holding SE : All divisions contribute to better-than-expect...

>A strong set of 9M figures beats expectations - 9M sales of € 890m (+3%) came in 1% above our (€ 886m) and 2% above the consensus compiled by the company of € 871m. Adjusted EBITDA of € 240m (-1%) is 5% above our estimates of € 229m and 8% above consensus of € 223m. The slightly lower profitability vs 9M 2023 (adjusted EBITDA margin of 27% vs 28%) still reflects the absence of sales from the extremely attractive contract with BioNTech, which still supported Q1 2023....

 PRESS RELEASE

EQS-News: Dermapharm Holding SE mit starkem dritten Quartal 2024, die ...

EQS-News: Dermapharm Holding SE / Schlagwort(e): Quartals-/Zwischenmitteilung/9-Monatszahlen Dermapharm Holding SE mit starkem dritten Quartal 2024, die französische Arkopharma erstmals wieder mit gestiegenem EBITDA gegenüber Vorjahr 14.11.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Dermapharm Holding SE mit starkem dritten Quartal 2024, die französische Arkopharma erstmals wieder mit gestiegenem EBITDA gegenüber Vorjahr   Konzernumsatz erhöht sich um 2,7 % auf 890,1 Mio. €. Das Wachstum der margenstarken „Markenarz...

 PRESS RELEASE

EQS-News: Dermapharm Holding SE posts strong results for Q3 2024, Arko...

EQS-News: Dermapharm Holding SE / Key word(s): Quarterly / Interim Statement/9 Month figures Dermapharm Holding SE posts strong results for Q3 2024, Arkopharma (France) back above prior-year EBITDA levels for first time 14.11.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Dermapharm Holding SE posts strong results for Q3 2024, Arkopharma (France) back above prior-year EBITDA levels for first time   Consolidated revenue up 2.7% to EUR 890.1 million. Growth in high-margin "Branded pharmaceuticals" more than offsets declining r...

 PRESS RELEASE

EQS-News: Dermapharm Holding SE: Margenstarkes Bestandsgeschäft des Ma...

EQS-News: Dermapharm Holding SE / Schlagwort(e): Halbjahresergebnis/Halbjahresbericht Dermapharm Holding SE: Margenstarkes Bestandsgeschäft des Markensegments treibt organisches Wachstum in deutschen und internationalen Gesellschaften 27.08.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Dermapharm Holding SE: Margenstarkes Bestandsgeschäft des Markensegments treibt organisches Wachstum in deutschen und internationalen Gesellschaften   Beeindruckendes organisches Wachstum des Bestandsgeschäfts im Markensegment in deuts...

 PRESS RELEASE

EQS-News: Dermapharm Holding SE: High-margin existing business in bran...

EQS-News: Dermapharm Holding SE / Key word(s): Half Year Results/Half Year Report Dermapharm Holding SE: High-margin existing business in branded pharmaceuticals segment drives organic growth at German and international companies 27.08.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Dermapharm Holding SE: High-margin existing business in branded pharmaceuticals segment drives organic growth at German and international companies   Impressive organic growth in existing branded pharmaceuticals business at German and internation...

 PRESS RELEASE

EQS-News: Nachhaltiges organisches Wachstum im margenstarken Bestandsg...

EQS-News: Dermapharm Holding SE / Schlagwort(e): Halbjahresergebnis/Vorläufiges Ergebnis Nachhaltiges organisches Wachstum im margenstarken Bestandsgeschäft der Markenarzneimittel 14.08.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Dermapharm Holding SE: Nachhaltiges organisches Wachstum im margenstarken Bestandsgeschäft der Markenarzneimittel   Starkes organisches Wachstum im Bestandsgeschäft der Markenarzneimittel in nahezu allen Märkten kompensiert das planmäßige Ende der pandemischen Phase der Impfstoffkooperation...

 PRESS RELEASE

EQS-News: Sustained organic growth in high-margin existing branded pha...

EQS-News: Dermapharm Holding SE / Key word(s): Half Year Results/Preliminary Results Sustained organic growth in high-margin existing branded pharmaceutical business 14.08.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Dermapharm Holding SE: Sustained organic growth in high- margin existing branded pharmaceutical business   Strong organic growth of existing branded pharmaceutical business across virtually every market compensates for effects from scheduled end of pandemic phase in vaccine cooperation Consolidated revenue an...

 PRESS RELEASE

EQS-News: Dermapharm Holding SE: Hauptversammlung beschließt Dividende...

EQS-News: Dermapharm Holding SE / Schlagwort(e): Hauptversammlung Dermapharm Holding SE: Hauptversammlung beschließt Dividendenausschüttung in Höhe von 0,88 € je Aktie 27.06.2024 / 18:15 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Dermapharm Holding SE: Hauptversammlung beschließt Dividendenausschüttung in Höhe von 0,88 € je Aktie   Prognose für 2024 bestätigt Vorstand und Aufsichtsrat mit großer Mehrheit entlastet Aktionäre beschließen Dividendenzahlung in Höhe von 0,88 € je Stückaktie Ausschüttungsquote von rund 78 % des Ko...

 PRESS RELEASE

EQS-News: Dermapharm Holding SE: Annual General Meeting resolves divid...

EQS-News: Dermapharm Holding SE / Key word(s): AGM/EGM Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share 27.06.2024 / 18:15 CET/CEST The issuer is solely responsible for the content of this announcement. Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share   2024 outlook confirmed Board of Management and Supervisory Board actions ratified with large majority Shareholders resolve dividend payment of EUR 0.88 per share Distribution ratio: approximately 78% of consolidated net...

Jerôme Bodin ... (+2)
  • Jerôme Bodin
  • Thomas Zlowodzki

ODDO BHF Small & MIDCAP MORNING NEWS - 05/16/2024

We have tactically downgraded the energy sector from Overweight to Neutral (excl. oil services on which we are maintaining our Overweight rating) and dropped Shell Plc from our Large Caps list. The IEA report has accelerated the downswing for the energy sector, which could continue in the days ahead. June will be a better month to come back to the sector. - ...

Jerôme Bodin ... (+2)
  • Jerôme Bodin
  • Thomas Zlowodzki

ODDO BHF Small & MIDCAP MORNING NEWS - 16/05/2024

Nous dégradons tactiquement à Neutre le secteur de l’énergie (hors Services Pétroliers sur lesquels nous conservons une opinion Surperformance) et faisons sortir Shell plc de notre liste Large Caps. Le rapport AIE a accéléré la baisse du secteur énergie, qui pourrait se poursuivre dans les jours qui viennent. Juin sera un meilleur mois pour revenir sur le secteur. - ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch